Iodinated 4,4’‐Bipyridines with Antiproliferative Activity Against Melanoma Cell Lines

In the last decade, biological processes involving halogen bond (HaB) as a leading interaction attracted great interest. However, although bound iodine atoms are considered powerful HaB donors, few iodinated new drugs were reported so far. Recently, iodinated 4,4’‐bipyridines showed interesting properties as HaB donors in solution and in the solid state. In this paper, a study on the inhibition activity of seven halogenated 4,4’‐bipyridines against malignant melanoma (MM) cell proliferation is described. Explorative dose/response proliferation assays were first performed with three 4,4’‐bipyridines by using four MM cell lines and the normal BJ fibroblast cell line as control. Among them, the A375 MM cell line was the most sensitive, as determined by MTT assays, which was selected to evaluate the antiproliferative activity of all 4,4’‐bipyridines. Significantly, the presence of an electrophilic iodine impacted the biological activity of the corresponding compounds. The 3,3’,5,5’‐tetrachloro‐2‐iodo‐4,4’‐bipyridine showed significant antiproliferation activity against the A375 cell line, and lower toxicity on BJ fibroblasts. Through in silico studies, the stereoelectronic features of possible sites determining the bioactivity were explored. These results pave the way for the utilization of iodinated 4,4’‐bipyridines as templates to design new promising HaB‐enabled inhibitors of MM cell proliferation. The antiproliferative activity of seven substituted 3,3’,5,5’‐tetrachloro‐4,4’‐bipyridines was evaluated against malignant melanoma (MM) cell lines. The 3,3’,5,5’‐tetrachloro‐2‐iodo‐4,4’‐bipyridine showed high activity on A375, and very low toxicity on control BJ fibroblasts. In silico studies confirmed the highest electrophilic properties for the iodine atoms contained in the most active compounds against MM cell line proliferation.